Lotilaner

Lotilaner, sold under the brand name Xdemvy, is an ectoparasiticide (anti-parasitic) medication used for the treatment of blepharitis (inflammation of the eyelid) caused by infestation by Demodex (tiny mites). It is used as an eye drop.

It was approved for medical use in the United States in July 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses
Lotilaner is indicated for the treatment of Demodex blepharitis.

Legal status
In March 2024, the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Lotimax, Chewable tablet, intended for use in dogs. The applicant for this veterinary medicinal product is Elanco GmbH. Lotimax was approved for medical use in the European Union in April 2024.

Veterinary uses
Lotilaner, sold under the brand name Credelio among others, is a veterinary medication used to control fleas and ticks in dogs and cats. It is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations including lone star tick (Amblyomma americanum), American dog tick (Dermacentor variabilis), black-legged tick (Ixodes scapularis), and brown dog tick (Rhipicephalus sanguineus). It is taken by mouth.

Lotilaner in combination with milbemycin oxime is sold under the brand name Credelio Plus. It is used in dogs to treat concurrent infestations with parasites living outside (ticks and/or fleas) and inside (worms) the animal's body.

Lotilaner (Lotimax) is used for the treatment of flea and tick infestations in dogs—treatment of demodicosis (caused by Demodex canis).

Research
Tarsus Pharmaceuticals has conducted phase II studies of lotilaner as a remedy to prevent tick bites in humans.